Browsing: Nordisk

Eli Lilly(NYSE: LLY) and Novo Nordisk(NYSE: NVO) are currently the leaders in the weight loss market. Their medicines have proved highly effective and generate billions in annual sales. However, drugs such as Wegovy and Zepbound are intended to treat patients with common forms of obesity. A little-known biotech, Rhythm Pharmaceuticals(NASDAQ: RYTM), has developed medicines for…

Novo Nordisk has launched a late-stage trial testing smaller doses of its Wegovy pill, seeking the lowest maintenance dose that still keeps weight off. 

Novo Nordisk has begun a placebo-controlled trial in search of “the most optimal lower dose” for its oral GLP-1 medicine for weight loss

Novo Nordisk has begun a late-stage clinical trial to evaluate whether lower doses of its oral pill, Wegovy, can still deliver weight reduction, reported Reuters

Novo Nordisk (ISIN DK0062498333) stock is trading in the mid-$40s per American depositary receipt after closing at $44.89 on August 17, 2026, leaving the shares down 11.8% year-to-date compared with a level of $50.88 at the start of 2026. Per recent market data, the stock was changing hands at $44.89 at 3:58 p.m. ET on…

Novo Nordisk has registered a first-in-human Phase I study of previously undisclosed obesity candidate NNC0721-8060, with a 142-participant program that will evaluate weight loss and include semaglutide alongside placebo despite the company keeping the asset’s target and modality under wraps

Novo Nordisk A/S (ISIN DK0062498333) stock is trading in the mid-$40 range for its US-listed ADR as of August 14, 2026, with a closing price of $45.91 and a modest decline of 1.73% on that day, underscoring a period of consolidation after its latest half-year earnings and guidance update. Per recent market data as of…

Readers who want to keep exploring related opportunities in healthcare and drug development can review 44 healthcare AI stocks

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide

Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market’s thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different…